Metabolic syndrome is associated with advanced prostate cancer in patients treated with radical retropubic prostatectomy: Results from a multicentre prospective study

BMC Cancer

Volumn 16, Issue 1, 2016, Pages

  De Nunzio, Cosimo ^a   Simone, Giuseppe ^b,c   Brassetti, Aldo ^a   Mastroianni, Riccardo ^b   Collura, Devis ^b,c   Muto, Giovanni ^b,c   Gallucci, Michele ^b   Tubaro, Andrea ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c MOLINETTE HOSPITAL   (Italy)

Author keywords

High grade; Metabolic syndrome; Prostate; Prostate cancer

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN; PROSTATE SPECIFIC ANTIGEN; TRIACYLGLYCEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGE; AGED; ANTIGEN DETECTION; ARTICLE; BLOOD SAMPLING; BODY MASS; CANCER GRADING; CANCER STAGING; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DISEASE ASSOCIATION; EUROPEAN; GLEASON SCORE; GLUCOSE BLOOD LEVEL; HUMAN; ITALY; LIPOPROTEIN BLOOD LEVEL; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MULTIVARIATE ANALYSIS; OBESITY; PREDICTION; PREOPERATIVE EVALUATION; PROSPECTIVE STUDY; PROSTATE CANCER; RADICAL RETROPUBIC PROSTATECTOMY; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; BLOOD; CLINICAL TRIAL; COMPLICATION; METABOLISM; MULTICENTER STUDY; PATHOLOGY; PROCEDURES; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK FACTOR;

AGED; BODY MASS INDEX; CHOLESTEROL, LDL; GLUCOSE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NEOPLASM STAGING; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK FACTORS; TRIGLYCERIDES; WAIST CIRCUMFERENCE;

EID: 84977570863     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-016-2442-7     Document Type: Article

References (36)

1. De Nunzio C, Freedland SJ, Miano R, Trucchi A, Cantiani A, Carluccini A, et al. Metabolic syndrome is associated with high grade gleason score when prostate cancer is diagnosed on biopsy. Prostate. 2011;71:1492-8. doi: 10.1002/pros.21364.
2. Esposito K, Chiodini P, Capuano A, Bellastella G, Maiorino MI, Parretta E, et al. Effect of metabolic syndrome and its components on prostate cancer risk: meta-analysis. J Endocrinol Invest. 2013;36:132-9. doi: 10.1007/BF03346748.
3. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37:1595-607.
4. Ozbek E, Otunctemur A, Dursun M, Sahin S, Koklu I, Erkoc M, et al. The Metabolic Syndrome is Associated with More Aggressive Prostate Cancer. Asian Pac J Cancer Prev. 2014;15:4029-32.
5. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421.
6. De Nunzio C, Presicce F, Lombardo R, Cancrini F, Petta S, Trucchi A, et al. Physical activity as a risk factor for prostate cancer diagnosis: a prospective biopsy cohort analysis. BJU Int 2015. doi: 10.1111/bju.13157.
7. De Nunzio C, Albisinni S, Freedland SJ, Miano L, Cindolo L, Finazzi Agrò E, et al. Abdominal obesity as risk factor for prostate cancer diagnosis and high grade disease: a prospective multicentre Italian cohort study. Urol Oncol. 2013;31:997-1002. doi: 10.1016/j.urolonc.2011.08.007.
8. De Nunzio C, Truscelli G, Trucchi A, Petta S, Tubaro M, Gacci M, et al. Metabolic abnormalities linked to an increased cardiovascular risk are associated with high-grade prostate cancer: a single biopsy cohort analysis. Prostate Cancer Prostatic Dis 2015. doi: 10.1038/pcan.2015.45.
9. Laukkanen JA, Laaksonen DE, Niskanen L, Pukkala E, Hakkarainen A, Salonen JT. Metabolic syndrome and the risk of prostate cancer in Finnish men: a population-based study. Cancer Epidemiol Biomarkers Prev. 2004;13:1646-50.
10. Bhindi B, Locke J, Alibhai SMH, Kulkarni GS, Margel DS, Hamilton RJ, et al. Dissecting the association between metabolic syndrome and prostate cancer risk: analysis of a large clinical cohort. Eur Urol. 2014;67:64-70. doi: 10.1016/j.eururo.2014.01.040.
11. Grundmark B, Garmo H, Loda M, Busch C, Holmberg L, Zethelius B. The metabolic syndrome and the risk of prostate cancer under competing risks of death from other causes. Cancer Epidemiol Biomarkers Prev. 2010;19:2088-96. doi: 10.1158/1055-9965.EPI-10-0112.
12. Kayali M, Balci M, Aslan Y, Bilgin O, Guzel O, Tuncel A, et al. The relationship between prostate cancer and presence of metabolic syndrome and late-onset hypogonadism. Urology. 2014;84:1448-52. doi: 10.1016/j.urology.2014.07.015.
13. Lund Håheim L, Wisløff TF, Holme I, Nafstad P. Metabolic syndrome predicts prostate cancer in a cohort of middle-aged Norwegian men followed for 27 years. Am J Epidemiol. 2006;164:769-74. doi: 10.1093/aje/kwj284.
14. Morote J, Ropero J, Planas J, Bastarós JM, Delgado G, Placer J, et al. Metabolic syndrome increases the risk of aggressive prostate cancer detection. BJU Int. 2013;111:1031-6. doi: 10.1111/j.1464-410X.2012.11406.x.
15. Sourbeer KN, Howard LE, Andriole GL, Moreira DM, Castro-Santamaria R, Freedland SJ, et al. Metabolic syndrome-like components and prostate cancer risk: results from the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) study. BJU Int. 2015;115:736-43. doi: 10.1111/bju.12843.
16. Tande AJ, Platz EA, Folsom AR. The metabolic syndrome is associated with reduced risk of prostate cancer. Am J Epidemiol. 2006;164:1094-102. doi: 10.1093/aje/kwj320.
17. Wallner LP, Morgenstern H, McGree ME, Jacobson DJ, St Sauver JL, Jacobsen SJ, et al. The effects of metabolic conditions on prostate cancer incidence over 15 years of follow-up: results from the Olmsted County Study. BJU Int. 2011;107:929-35. doi: 10.1111/j.1464-410X.2010.09703.x.
18. Xiang Y, Xiong H, Cui Z, Jiang S, Xia Q, Zhao Y, et al. The association between metabolic syndrome and the risk of prostate cancer, high-grade prostate cancer, advanced prostate cancer, prostate cancer-specific mortality and biochemical recurrence. J Exp Clin Cancer Res. 2013;32:9. doi: 10.1186/1756-9966-32-9.
19. Abdeen Z, Jildeh C, Dkeideek S, Qasrawi R, Ghannam I, Al Sabbah H. Overweight and obesity among Palestinian adults: analyses of the anthropometric data from the first national health and nutrition survey (1999-2000). J Obes. 2012;2012:213547. doi: 10.1155/2012/213547.
20. Frese EM, Fick A, Sadowsky HS. Blood pressure measurement guidelines for physical therapists. Cardiopulm Phys Ther J. 2011;22:5-12.
21. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol. 2014;65:124-37. doi: 10.1016/j.eururo.2013.09.046.
22. Epstein JI, Srigley J, Grignon D, Humphrey P. Recommendations for the reporting of prostate carcinoma. Hum Pathol. 2007;38:1305-9. doi: 10.1016/j.humpath.2007.05.015.
23. Eble JN, Sauter G, Epstein JI, Sesterhenn IA. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. IARC Press 2004:1-353. doi: 10.1016/j.urology.2004.09.048.
24. Rodrigues G, Warde P, Pickles T, Crook J, Brundage M, Souhami L, et al. Pre-treatment risk stratification of prostate cancer patients: A critical review. Can Urol Assoc J. 2012;6:121-7. doi: 10.5489/cuaj.11085.
25. Freedland SJ, Isaacs WB, Platz EA, Terris MK, Aronson WJ, Amling CL, et al. Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study. J Clin Oncol. 2005;23:7546-54. doi: 10.1200/JCO.2005.05.025.
26. Freedland SJ, Wieder JA, Jack GS, Dorey F, DeKernion JB, Aronson WJ. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score. J Urol. 2002;168:110-5. doi: 10.1097/00005392-200207000-00025.
27. Oh JJ, Hong SK, Lee JK, Lee BK, Lee S, Kwon OS, et al. Prostate-specific antigen vs prostate-specific antigen density as a predictor of upgrading in men diagnosed with Gleason 6 prostate cancer by contemporary multicore prostate biopsy. BJU Int. 2012;110:494-9. doi: 10.1111/j.1464-410X.2012.11182.x.
28. Kassouf W, Nakanishi H, Ochiai A, Babaian KN, Troncoso P, Babaian RJ. Effect of prostate volume on tumor grade in patients undergoing radical prostatectomy in the era of extended prostatic biopsies. J Urol. 2007;178:111-4. doi: 10.1016/j.juro.2007.03.013.
29. Corcoran NM, Casey RG, Hong MKH, Pedersen J, Connolly S, Peters J, et al. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume. BJU Int. 2012;110:36-42. doi: 10.1111/j.1464-410X.2011.10681.x.
30. Kundu SD, Roehl KA, Yu X, Antenor JA V, Suarez BK, Catalona WJ. Prostate specific antigen density correlates with features of prostate cancer aggressiveness. J Urol. 2007;177:505-9. doi: 10.1016/j.juro.2006.09.039.
31. Beebe-Dimmer JL, Nock NL, Neslund-Dudas C, Rundle A, Bock CH, Tang D, et al. Racial differences in risk of prostate cancer associated with metabolic syndrome. Urology. 2009;74:185-90. doi: 10.1016/j.urology.2009.03.013.
32. Kheterpal E, Sammon JD, Diaz M, Bhandari A, Trinh Q-D, Pokala N, et al. Effect of metabolic syndrome on pathologic features of prostate cancer. Urol Oncol. 2013;31:1054-9. doi: 10.1016/j.urolonc.2011.12.012.
33. Sfanos KS, De Marzo AM. Prostate cancer and inflammation: the evidence. Histopathology. 2012;60:199-215. doi: 10.1111/j.1365-2559.2011.04033.x.
34. Powell IJ, Bollig-Fischer A. Minireview: the molecular and genomic basis for prostate cancer health disparities. Mol Endocrinol. 2013;27:879-91. doi: 10.1210/me.2013-1039.
35. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Grönberg H, Drake CG, et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer. 2007;7:256-69. doi: 10.1038/nrc2090.
36. De Nunzio C, Aronson W, Freedland SJ, Giovannucci E, Parsons JK. The correlation between metabolic syndrome and prostatic diseases. Eur Urol. 2012;61:560-70. doi: 10.1016/j.eururo.2011.11.013.